Pharmacologic management of Parkinson disease: Choice of initial therapy in early disease

Journal of Pharmacy Practice

Volumn 21, Issue 4, 2008, Pages 244-253

  Chen, Jack J ^a   Pahwa, Rajesh ^b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine agonists; Levodopa; Monoamine oxidase inhibitors; Parkinson's disease; Pramipexole; Rasagiline; Ropinirole; Selegiline

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; LEVODOPA; MADOPAR CR; MIDODRINE; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE; PROCYCLIDINE; QUETIAPINE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOCOPHEROL; TRIHEXYPHENIDYL; UBIDECARENONE;

BRAIN DEPTH STIMULATION; CARDIAC VALVE FIBR; CLINICAL ASSESSMENT; COMPRESSION GARMENT; CONFUSION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DYSKINESIA; EARLY DIAGNOSIS; HALLUCINATION; HALLUCINOSIS; HUMAN; IMPULSE CONTROL DISORDER; KIDNEY DYSFUNCTION; LEG EDEMA; LIVEDO RETICULARIS; LUNG FIBROSIS; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PARKINSON DISEASE; PSYCHOSIS; RETROPERITONEAL FIBROSIS; REVIEW; RISK ASSESSMENT; SOMNOLENCE; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

EID: 47649086388     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008318129     Document Type: Review

References (57)

1. Chen JJ, Swope DM Pharmacotherapy for Parkinson's disease. Pharmacotherapy. 2007 ; 27 (pt 2). 161S - 173S.
2. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA. 2000 ; 284: 1931-1938.
3. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesia and response fluctuations in young-onset Parkinson disease. Neurology. 1991 ; 41 (pt 1). 202-205.
4. Grandas F., Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesia in Parkinson's disease. J Neurol. 1999 ; 246: 1127-1133.
5. Wu RM, Chiu HC, Wang M., Chen RC Risk factors on the occurrence of response fluctuations and dyskinesia in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1993 ; 5: 127-133.
6. Koller WD, Hutton TJ, Tolosa E.,, et al. the Carbidopa/ Levodopa Study Group. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology. 1999 ; 53: 1012-1019.
7. Chen JJ, Shimomura SK Parkinsonism. In: Helms RA, Quan DJ, eds. The Textbook of Therapeutics: Drug and Disease Management. 8 th ed. Baltimore ; 2006: 1646-1670.
8. Curran MP, Perry CM Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs. 2004 ; 64: 2125-2141.
9. Frucht S., Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999 ; 52: 1908-1910.
10. Zanettini R., Antonini A., Gatto G., et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007 ; 356: 39-46.
11. Goetz CG, Blasucci L., Stebbins GT Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? Neurology. 1999 ; 52: 1227-1229.
12. Montastruc JL, Rascol O., Rascol A. A randomized controlled study of bromocriptine vs levodopa in previously untreated parkinsonian patients: a 3-year follow-up. J Neurol Neurosurg Psychiatry. 1989 ; 52: 773-775.
13. Shannon KM, Bennett JP, Friedman JH Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease: The Pramipexole Study Group. Neurology. 1997 ; 49: 724-728.
14. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA. 1997 ; 278: 125-130.
15. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. A 4-year randomized controlled trial. Arch Neurol. 2004 ; 61: 1044-1053.
16. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997 ; 49: 393-399.
17. Rascol O., Brooks DJ, Korczyn AD, et al for the 056 Study Group. A 5-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 ; 342: 1484-1491.
18. Korczyn AD, Brunt ER, Larsen JP, et al for the 053 Study Group. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology. 1999 ; 53: 364-370.
19. Hauser RA, Rascol O., Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007 ; 22: 2409-2417.
20. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003 ; 60: 1721-1728.
21. Watts RL, Jankovic J., Waters C., et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007 ; 68: 272-276.
22. Giladi N., Boroojerdi B., Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007 ; 22: 2398-2404.
23. LeWitt PA, Boroojerdi B., MacMahon D., et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 ; 30: 256-265.
24. Chen JJ Optimizing use of a dopamine agonist in Parkinson's disease. Pharmacy Times. 2007 ; 73: 111-121.
25. Palhagen S., Heinonen EH, Hagglund J., et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology. 1998 ; 51: 520-525.
26. Allain H., Pollack P., Neukirch HC Members of the French Selegiline Multicenter Trial. Symptomatic effect of selegiline in de novo Parkinson's patients. Mov Disord. 1993 ; 8 (suppl 1). S36 - S40.
27. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH Selegiline in de novo Parkinson's patients: the Finnish Study. Mov Disord. 1993 ; 8 (suppl 1). S41 - S44.
28. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 ; 29: 1825-1849.
29. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol. 2002 ; 59: 1937-1943.
30. Lew M., Hauser R., Hurtig H., Ondo W., Wojcieszek J. Long-term efficacy of rasagiline in Parkinson's disease. Mov Disord. 2005 ; 20 (suppl 10). S75.
31. Panisset M., Schwid S., Ondo W., et al. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson's disease. Mov Disord. 2007 ; 223 (suppl 16). S104 - S105.
32. Blanpied TA, Boeckman FA, Aizenman E., Johnson JW Trapping channel block of NMDA-activated responses by amantadine and memantine. N Neurophysiol. 1997 ; 77: 309-323.
33. Factor SA, Molho ES Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Mov Disord. 1999 ; 14: 515-517.
34. Schapira AHV, Olanow CW Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004 ; 291: 358-364.
35. Jordan J., Cena V., Prehn JH Mitochondrial control of neuron death and its role in neurodegenerative disorders. J Physiol Biochem. 2003 ; 59: 129-141.
36. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003 ; 54: 93-101.
37. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002 ; 287: 1653-1661.
38. Ikawa K., Watanabe A., Kaneno S., Toru M. Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol. 1993 ; 250: 261-266.
39. Cho S., Neff NH, Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol. 1997 ; 323: 149-157.
40. Guttman M., Stewart D., Hussey D., Wilson A., Houle S., Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001 ; 56: 1559-1564.
41. Scheller D., Chan P., Li Q., et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol. 2007 ; 203: 415-422.
42. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989 ; 321: 1364-1371.
43. Birkmayer W., Knoll J., Riederer P., et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm. 1985 ; 64: 113-127.
44. Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993 ; 328: 176-183.
45. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996 ; 39: 29-36.
46. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol. 1996 ; 39: 37-45.
47. Giladi N., McDermott MP, Fahn S., et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology. 2001 ; 56: 1712-1721.
48. Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson disease: a randomized placebo-controlled extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism trial. Ann Neurol. 2002 ; 51: 604-612.
49. Wan FJ, Lin HC, Huang KL, et al. Systemic administration of D-amphetamine induces long-lasting oxidative stress in the rat striatum. Life Sci. 2000 ; 66: PL205 - PL212.
50. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004 ; 61: 561-566.
51. Leber P. Slowing the progression of Alzheimer disease: methodologic issues [abstract]. Alzheimer Dis Assoc Disord. 1997 ; 11 (suppl 5). S10 - S21.
52. Hauser R., Lew M., Hurtig H., Ondo W., Wojcieszek J. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Mov Disord. 2005 ; 20 (suppl 10). S75.
53. Matthew RT, Yang L., Browne S., et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998 ; 21: 8892-8897.
54. Muller T., Buttner T., Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003 ; 341: 201-204.
55. Shults CW, Oakes D., Kieburtz K., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 ; 59: 1541-1550.
56. Storch A., Jost WH, Vieregge P., et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007 ; 64: 938-944.
57. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 ; 68: 20-28.